Mission and Values
Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for a range of urologic conditions.
Our goal is to be the leading specialty company, recognized and trusted by patients and providers for our commitment to urology.
At Urovant Sciences, we aim to advance urological patient care through execution of our core values:
Integrity and Compassion
Our commitment to improving patients’ lives begins with personal integrity and how we treat each other.
Bold Innovation
We deliver bold innovation through diversity of thought, openness to new ideas and adaptation to change.
Achievement Through Collaboration
We achieve excellence by uniquely optimizing our collective individual strengths and expertise.
Urovant Sciences is driving scientific innovation to improve the quality of life for patients living with urological conditions.
Our current area of research focus is Overactive Bladder (OAB). We are currently investigating treatments for OAB in men with benign prostatic hyperplasia (BPH), as well as third line treatments for OAB symptoms in patients who have failed oral pharmacologic therapy.
2017
Vibegron, a β3-adrenergic agonist in development to treat symptoms of overactive bladder (OAB), is acquired as the first compound in the portfolio.
Urovant Sciences establishes corporate offices in Irvine, California.
2018
Urovant Sciences raises $140M in its initial public offering on the NASDAQ Global Select Market under the symbol UROV.
Acquisition of URO-902, the second compound in the portfolio, kickstarts the development of a gene therapy for the treatment of symptoms of OAB.
Phase 3 study of vibegron for patients with OAB begins.
2019
Urovant Sciences launches the Phase 3 study of vibegron for men with benign prostatic hyperplasia (BPH) and OAB.
Phase 2 study of URO-902 for patients with OAB begins.
Primary shareholder, Roivant Sciences, sells its majority ownership of Urovant Sciences to Sumitovant Biopharma Ltd., which is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd.
Urovant Sciences files New Drug Application (NDA) with U.S. Food and Drug Administration for vibegron in OAB.
2020
Urovant Sciences team grows to 135 employees across 25 states.
Urovant Sciences is committed to developing medicines for urological conditions that allow people to live healthier and happier lives.
Our approach is rooted in social responsibility. We are committed to the health and well-being of the patients and healthcare providers we serve, to our employees, and to the communities in which we operate. Urovant Sciences supports policies that improve public health and access to life-impacting therapies regardless of race, ethnicity or ability to pay.
Patent Notice
Please see the following list for U.S. Patents covering Urovant Sciences' Products.